+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating Enzomenib DSP-5336, an oral drug, in patients with various types of acute leukemia, including relapsed or refractory acute myeloid leukemia AML, acute lymphocytic leukemia ALL, and acute leukemia of ambiguous lineage. The study also includes patients with high-risk myelodysplastic syndromes MDS and relapsed multiple myeloma MM in selected sites. This phase 12 trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of DSP-5336 alone or combined with standard AML treatments, particularly in patients with specific genetic mutations like MLL rearrangement or NPM1 mutation. The study involves dose escalation and dose expansion of DSP-5336 administered orally. Participants may receive DSP-5336 alone or combined with standard AML regimens such as venetoclax plus azacitidine or intensive chemotherapy with cytarabine and daunorubicin 73. Different study arms include patients with or without certain medications like CYP3A4 inhibitor azoles, and those with specific genetic profiles. The trial evaluates recommended phase 2 doses for various patient groups and combination treatments. Participants will undergo assessments including monitoring for adverse events within 30 days after the last dose and evaluation of clinical responses approximately six months after treatment begins. Researchers will collect blood and bone marrow samples for genomic analysis and track drug levels in the body. Safety labs, ECGs, physical exams, and patient questionnaires will be performed throughout the study. The trial includes long-term follow-up of overall survival up to two years after treatment ends, with visits and tests scheduled to monitor health and treatment effects.

Age: 12Years +All GendersPhase 1Phase 2
104 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of JNJ-79635322 compared to teclistamab in adults with relapsed or refractory multiple myeloma who have received 1 to 3 prior treatments, including an anti-CD38 antibody and lenalidomide. This phase 3 randomized study aims to assess how well these treatments work in controlling the disease and improving patient outcomes. Participants will receive subcutaneous injections of either JNJ-79635322 for a limited time or until intolerable side effects occur, or teclistamab as a subcutaneous injection until disease progression or intolerable toxicity. The study compares these two treatment approaches in parallel groups to observe differences in clinical response and safety. During the study, participants will be regularly monitored with laboratory tests and evaluations to measure responses such as complete response, progression-free survival, and quality of life. Researchers will track side effects, symptoms, and functioning over up to approximately 41 months. The study includes detailed assessments using questionnaires and laboratory parameters to understand treatment impact and safety throughout the participation period.

Age: 18Years +All GendersPhase 3
173 locations
P

Actively Recruiting

Researchers are evaluating the safety and effects of elritercept, a recombinant fusion protein, in treating anemia linked to lower-risk myelodysplastic syndromes MDS in adults. The study focuses on how well participants tolerate different doses of elritercept and its impact on anemia progression and healthy red blood cell production. This trial is a Phase 2, open-label study assessing elritercepts potential benefits for adults with very low, low, or intermediate risk MDS. Participants receive elritercept as a subcutaneous injection every 4 weeks on Day 1 of each 28-day cycle. Dose levels range from 0.75 mgkg to 5.0 mgkg, with treatment continuing for up to 24 cycles following an initial 4-cycle period. Dose adjustments may occur based on individual response. Special cohorts include participants with ring sideroblast-positive MDS, non-ring sideroblast MDS, chronic myelomonocytic leukemia with anemia, and those with iron overload or previous treatment with luspatercept. Some participants may continue treatment in a long-term extension phase lasting approximately 122 months. During the study, participants undergo regular monitoring for treatment-emergent adverse events and disease progression to higher-risk MDS or acute myeloid leukemia. Researchers assess red blood cell transfusion independence, hematologic improvement, erythropoietic response, hemoglobin changes, and red cell parameters over the treatment period, which may last up to 11.2 years. The study includes evaluations of safety, efficacy, and long-term effects of elritercept, with ongoing follow-up visits and assessments to track participants health and response to treatment.

Age: 18Years +All GendersPhase 2
53 locations
P

Actively Recruiting

Researchers are evaluating an experimental drug called REGN5837 in combination with another drug, odronextamab, for adults with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas B-NHLs. The study aims to find a safe dose of REGN5837 when combined with odronextamab and then assess how well this combination works. Additional questions include side effects, drug levels in the blood, and whether the body develops antibodies that might affect the drugs action. The study has two parts. The first part involves dose escalation to determine a safe dose of REGN5837 combined with odronextamab. The second part uses the safe dose found to evaluate the treatments effectiveness. Both drugs are administered according to the study protocol. The study does not use randomization or masking. Participants will be monitored for side effects and adverse events for up to approximately five years. Researchers will measure drug concentrations in the blood, antibody responses, and cancer response using the Lugano Classification. Tumor biopsies may be required during the dose expansion phase. The study includes regular assessments and follows participants long term to evaluate treatment safety and outcomes.

Age: 18Years +All GendersPhase 1
20 locations
O

Actively Recruiting

Researchers are collecting clinical data to evaluate the ongoing safety and performance of commercially approved Biosense Webster Inc. BWI medical devices used during routine cardiac arrhythmia mapping and ablation procedures. This observational study aims to confirm the safety and effectiveness of these devices in real-world settings and expand knowledge about their use in treating cardiac arrhythmias such as atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia. Participants diagnosed with cardiac arrhythmias who are scheduled for catheter ablation using BWI therapeutic catheters, including Varipulse Catheter and Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, will be observed during their routine clinical care. No specific interventions are assigned by the study instead, participants undergo standard treatment with these devices as part of their medical management. During the study, participants will be monitored for adverse events related to the devices and procedures, both shortly after ablation and up to one year. Researchers will track arrhythmia outcomes and repeated procedures as part of routine follow-up. Data collection includes safety assessments, arrhythmia recurrence, and hospitalization events. Participation may last up to a year, with ongoing observation during routine healthcare visits.

All AgesAll Genders
47 locations
S

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with ALK gene rearrangement treated with next-generation tyrosine kinase inhibitors TKIs as first-line therapy. This prospective study, part of the national EXPLORE ALK cohort, aims to understand the biological characteristics and resistance mechanisms of this cancer type. It involves patients with stage IIIB or IV NSCLC who are not eligible for curative locoregional treatment and have confirmed ALK rearrangement. The study collects tumor tissue samples at diagnosis and at disease progression, if available, to analyze ALK fusion partners, variants, and co-mutations using RNA sequencing. Blood samples are taken at diagnosis, first tumor evaluation, and disease progression to analyze circulating tumor DNA ctDNA with next-generation sequencing. Treatments studied include alectinib, brigatinib, lorlatinib, and entrectinib, either marketed or under early access programs. Participants provide blood samples and allow use of tumor tissue for centralized biological analyses. Researchers measure progression-free survival up to 72 months as the primary outcome, along with overall survival, response rates, duration of response, ctDNA clearance, and resistance mechanisms associated with treatment and ALK fusion partners. The study involves regular evaluations over several years to monitor treatment outcomes and biological changes.

Age: 18Years +All GendersPhase Not Applicable
46 locations
C

Actively Recruiting

Researchers are evaluating the best anesthetic approach for patients with severe ischemic stroke undergoing mechanical thrombectomy MT, a procedure to open blocked brain vessels. This trial compares general anesthesia GA, which requires breathing support and induces unarousable sleep, with procedural sedation PS, which uses a lighter sedation without respiratory assistance. The study aims to determine which method better improves functional independence three months after stroke, addressing conflicting results from previous smaller trials. Participants will receive either GA, involving intubation and controlled ventilation with specific anesthetic drugs and strict blood pressure management, or PS, involving lighter sedation with spontaneous breathing and targeted sedation medications. Both groups will be monitored closely during the procedure and postoperatively, with vital signs, blood pressure, blood sugar, and oxygen levels carefully controlled. After the intervention, patients are transferred to stroke care units for further monitoring including brain imaging within 24 to 48 hours. Throughout their hospital stay and after discharge, participants will be assessed for functional outcomes using the modified Rankin Scale at 90 days, along with other measures such as cognitive function, quality of life, and stroke severity scales. Researchers will evaluate procedural success, complications, and recovery progress. Follow-up includes telephone interviews at three months to determine independence in daily life and overall recovery, with the study concluding around three years after enrollment begins.

Age: 18Years +All GendersPhase Not Applicable
16 locations
S

Actively Recruiting

Diabetic foot ulcer DFU is a common and serious complication in people with diabetes, often leading to lower-limb amputation and linked to decreased quality of life and increased health care costs. This research aims to better understand why patients with DFU have a higher risk of premature death, exploring factors beyond cardiovascular disease such as inflammation, infections, and cancers. The study is a prospective, observational, multi-center cohort conducted in France. Adults with diabetes and DFU will be followed for up to 5 years to measure outcomes including mortality rates, causes of death, and prognostic factors. The study will include a 3-year enrollment period starting in 2020. Researchers will also assess changes in health-related quality of life and the economic burden of DFU using healthcare claims data. Participants will be monitored regularly over 5 years or until death. Researchers will collect data on survival without active or recurrent DFU, major limb and vascular events, and overall health status. The study will provide important data on the course of DFU and its impact on patients lives and health care systems.

Age: 18Years +All Genders
26 locations
E

Actively Recruiting

Researchers are evaluating whether skipping a routine urine bacterial culture before transurethral resection of the bladder TURB surgery is not worse than doing the culture in preventing febrile urinary tract infections UTIs within 30 days after surgery. TURB is a common surgery for bladder cancer diagnosis and treatment, and current guidelines recommend urine culture screening to detect asymptomatic bacteriuria and guide antibiotic use before surgery. However, the link between preoperative urine culture and postoperative infections is unclear, and antibiotic resistance is a growing concern. The study compares two groups one undergoing systematic urine bacterial culture before TURB with antibiotics given if positive, and the other not having urine culture before surgery. The urine culture is done 4 to 10 days before TURB in the culture group. Antibiotic treatment starts 48 hours before surgery and lasts up to 7 days if the culture is positive. The goal is to assess if avoiding preoperative urine cultures can reduce unnecessary antibiotic use without increasing infection rates. Participants will be monitored for 30 days after TURB surgery for febrile UTIs and other complications. Researchers will track surgery delays, hospital stays, readmissions, antibiotic prescriptions, infection timing, and survival. Data collection includes follow-up visits and assessments within 30 days post-surgery. This trial aims to provide evidence on the necessity of preoperative urine culture screening and its impact on postoperative infection rates and antibiotic use.

Age: 18Years +All GendersPhase Not Applicable
15 locations
F

Actively Recruiting

Colorectal cancer is a leading cause of cancer-related death, with many patients developing liver metastases that are often difficult to remove surgically. This trial focuses on first-line treatment for patients with metastatic colorectal cancer limited to the liver, aiming to evaluate the effectiveness of combining systemic chemotherapy, targeted therapies, and intra-arterial oxaliplatin chemotherapy. The study seeks to improve tumor response rates, progression-free survival, and overall survival in this patient group. Participants will receive one of four treatment regimens involving combinations of oxaliplatin administered either intra-arterially or intravenously, along with folinic acid, 5-fluorouracil 5-FU, irinotecan, and targeted therapies such as panitumumab or bevacizumab depending on RAS mutation status. Treatment cycles occur every 15 days, with dosing tailored to each arm including variations in drug delivery methods and combinations. The trial includes both experimental and reference treatment arms to compare outcomes. Throughout the study, participants will be monitored for progression-free survival up to 24 months after randomization. Assessments include measuring tumor response by RECIST criteria and evaluating liver metastases. Safety and tolerability will be tracked through laboratory tests and clinical evaluations, while participants eligibility and health status will be closely followed. The study duration extends up to 2028, with ongoing data collection to assess long-term outcomes and treatment effects.

Age: 18Years +All GendersPhase 3
49 locations

1-10 of 11

1